The DOI matches its Crossref record; 42 of the 43 references it cites were found in a registry or an index.
Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia
Open accessAbstract
Acetyl coenzyme A (AcCoA) is the central biosynthetic precursor for fatty-acid synthesis and protein acetylation. In the conventional view of mammalian cell metabolism, AcCoA is primarily generated from glucose-derived pyruvate through the citrate shuttle and ATP citrate lyase in the cytosol. However, proliferating cells that exhibit aerobic glycolysis and those exposed to hypoxia convert glucose to lactate at near-stoichiometric levels, directing glucose carbon away from the tricarboxylic acid cycle and fatty-acid synthesis. Although glutamine is consumed at levels exceeding that required for nitrogen biosynthesis, the regulation and use of glutamine metabolism in hypoxic cells is not well understood. Here we show that human cells use reductive metabolism of α-ketoglutarate to synthesize AcCoA for lipid synthesis. This isocitrate dehydrogenase-1 (IDH1)-dependent pathway is active in most cell lines under normal culture conditions, but cells grown under hypoxia rely almost exclusively on the reductive carboxylation of glutamine-derived α-ketoglutarate for de novo lipogenesis. Furthermore, renal cell lines deficient in the von Hippel-Lindau tumour suppressor protein preferentially use reductive glutamine metabolism for lipid biosynthesis even at normal oxygen levels. These results identify a critical role for oxygen in regulating carbon use to produce AcCoA and support lipid synthesis in mammalian cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Both HIF-1α and HIF-2α activation promotes the upregulation of the glutamine transporter, SLC38A2, which increases the dependency of cells to glutamine and correlates with poorer survival in patients with breast cancer [58]”
From The HIF Axes in Cancer - Angiogenesis, Metabolism and Immune-Modulation (2025) · cites this paper as [58]
Experimental — accuracy not yet measuredIn the citing paper
“Similarly, checkpoint kinase 1 (CHK1) inhibitors625–627 and glutaminase (GLS) inhibitors628–634 are also considered potential candidates for treating Myc-overexpressing cancers.”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [631]
In the citing paper
“Citrate, generated by reductive carboxylation of α-KG, is especially crucial for lipid synthesis under low-oxygen conditions24,25.”
From Glutamine reliance in cell metabolism (2020) · cites this paper as [24]
In the citing paper
“and switch the fate of glutamine from the oxidative pathway into the reductive carboxylation pathway24.”
From Glutamine reliance in cell metabolism (2020) · cites this paper as [24]
In the citing paper
“In the context of constitutive HIF-2α stabilization75 or a defective mitochondrial electron transport chain76, glutamine-derived α-KG is reductively carboxylated through the consumption of NADPH by IDH2 to generate citrate.”
From Glutamine reliance in cell metabolism (2020) · cites this paper as [75]
In the citing paper
“Glutamine acts as an alternative fuel for fatty acid synthesis, supplying citrate via mitochondrial reductive carboxylation, especially under hypoxic conditions74,75.”
From Glutamine reliance in cell metabolism (2020) · cites this paper as [75]
In the citing paper
“Alternatively, proliferating cells under hypoxia have been reported to predominantly reductively carboxylate glutamine generated α-ketoglutarate through IDH 1/2 to generate M5 citrate (Figure 4A) (Metallo, 2012).”
From Tumor microenvironment derived exosomes pleiotropically modulate cancer cell metabolism (2016) · cites this paper as Metallo, 2012
In the citing paper
“Previous reports showed that reductive carboxylation is a critical pathway to support the growth of tumor cells under hypoxia (Metallo, 2012; Mullen, 2012).”
From Tumor microenvironment derived exosomes pleiotropically modulate cancer cell metabolism (2016) · cites this paper as Metallo, 2012
In the citing paper
“The upregulation of the reductive carboxylation pathway enhances cancer cells proliferation (Metallo, 2012; Mullen, 2012; Wise et al., 2011).”
From Tumor microenvironment derived exosomes pleiotropically modulate cancer cell metabolism (2016) · cites this paper as Metallo, 2012
In the citing paper
“For example, under conditions of hypoxia or impaired mitochondrial respiration, certain reactions of the TCA cycle reverse to support glutamine-dependent reductive carboxylation (92, 122, 123).”
From Regulation and function of the mammalian tricarboxylic acid cycle (2023) · cites this paper as [122]
In the citing paper
“In a process referred to as reductive carboxylation, a section of the TCA cycle reverses itself, converting α-ketoglutarate into citrate, which can be then used to generate a source of cytosolic acetyl-CoA (Metallo et al., 2012; Wise et al., 2011).”
From The emerging hallmarks of cancer metabolism (2016) · cites this paper as Metallo et al., 2012
In the citing paper
“Citrate is generated by citrate synthase (CS) or through the reduction of α-ketoglutarate by isocitrate dehydrogenase (IDH).79–81”
From The multifaceted contributions of mitochondria to cellular metabolism (2018) · cites this paper as [79]
In the citing paper
“Citrate levels, however, were markedly decreased in Mpc1KD or Mpc2KD (Mpc1/2KD) cells, as this metabolite is generated predominantly from pyruvate-derived AcCoA under normal growth conditions (Metallo et al., 2012).”
From Regulation of Substrate Utilization by the Mitochondrial Pyruvate Carrier (2014) · cites this paper as Metallo et al., 2012
In the citing paper
“Glutamine can contribute carbon to fatty acid synthesis via reductive carboxylation or oxidative glutaminolysis.”
From Regulation of Substrate Utilization by the Mitochondrial Pyruvate Carrier (2014) · cites this paper as Metallo et al., 2012
In the citing paper
“The former pathway is highly active in cells proliferating under hypoxia or those with a compromised respiratory chain (Metallo et al., 2012; Mullen et al., 2012; Scott et al., 2011; Wise et al., 2011), while the latter pathway has been observed in B cell lymphoma (Le et al., 2012).”
From Regulation of Substrate Utilization by the Mitochondrial Pyruvate Carrier (2014) · cites this paper as Metallo et al., 2012
In the citing paper
“This switch to reductive versus oxidative metabolism of α-KG is regulated in part by HIF-1α (71, 72), although the exact mechanism by which HIF-1α does so remains unclear.”
From Fueling Immunity: Insights into Metabolism and Lymphocyte Function (2013) · cites this paper as [71]
In the citing paper
“Although oxidation of glutamine-derived α-KG in the TCA cycle serves as a minor source of lipogenic acetyl-CoA under normal growth conditions, α-KG can be converted to citrate through reductive carboxylation under conditions of stress such as hypoxia or mitochondrial dysfunction (70–72).”
From Fueling Immunity: Insights into Metabolism and Lymphocyte Function (2013) · cites this paper as [71]
In the citing paper
“The work from Metallo and colleagues (71) suggests that T cells can use reductive glutamine metabolism for fatty acid biosynthesis under hypoxic conditions.”
From Fueling Immunity: Insights into Metabolism and Lymphocyte Function (2013) · cites this paper as [71]
In the citing paper
“In place of oxidative metabolism of both glucose and glutamine, these cancers preferentially perform reductive and carboxylating biosynthetic reactions from glutamine carbon (Le et al., 2012; Metallo et al., 2012; Mullen et al., 2012; Wise et al., 2011).”
From Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate (2012) · cites this paper as Metallo et al., 2012
In the citing paper
“Recently three independent reports implicated IDH-dependent reductive carboxylation as playing a particularly important role in proliferating cells that exhibit decreased flux of glucose-derived pyruvate into the mitochondria. This occurs in hypoxic cells or in cells harboring defects in mitochondrial oxidative phosphorylation (Metallo et al., 2012; Mullen et al., 2012; Wise et al., 2011).”
From Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate (2012) · cites this paper as Metallo et al., 2012
In the citing paper
“tumor cells with mutations in the TCA cycle or ETC (Mullen et al., 2011), or with hypoxia-induced suppression of oxidative metabolism (Metallo et al., 2011; Scott et al., 2011; Wise et al., 2011) use reductive carboxylation of α-KG to produce citrate and other precursors during growth.”
From Cellular Metabolism and Disease: What Do Metabolic Outliers Teach Us? (2012) · cites this paper as Metallo et al., 2011
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex
Sarbassov, D. D., Guertin, D. A., Ali, S. M., & Sabatini, D. M. (2005) · Science · doi:10.1126/science.1106148 · Cited by 6,216
Jaakkola, P., Mole, D. R., Tian, Y.-M., Wilson, M. I., Gielbert, J., Gaskell, S. J., Kriegsheim, A. V., Hebestreit, H. F., Mukherji, M., Schofield, C. J., et al. (2001) · Science · doi:10.1126/science.1059796 · Cited by 5,535
HIFα Targeted for VHL-Mediated Destruction by Proline Hydroxylation: Implications for O 2 Sensing
Ivan, M., Kondo, K., Yang, H., Kim, W., Valiando, J., Ohh, M., Salic, A., Asara, J. M., Lane, W. S., & Kaelin Jr., W. G. (2001) · Science · doi:10.1126/science.1059817 · Cited by 4,735 · cited 1×
“The von Hippel–Lindau (VHL) tumour suppressor protein is frequently lost in renal cell carcinoma (RCC) and results in a state of ‘pseudohypoxia’ by activating HIF signallin”
BackgroundKim, J.-W., Tchernyshyov, I., Semenza, G. L., & Dang, C. V. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.02.002 · Cited by 3,905
T cell receptor antagonist peptides induce positive selection.
Hogquist, K., Jameson, S., Heath, W., Howard, J. L., Bevan, M., & Carbone, F. (1994) · Cell · doi:10.1016/0092-8674(94)90169-4 · Cited by 3,252
DeBerardinis, R. J., Mancuso, A., Daikhin, E., Nissim, I., Yudkoff, M., Wehrli, S., & Thompson, C. B. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709747104 · Cited by 2,622
ATP-citrate lyase links cellular metabolism to histone acetylation
Wellen, K. E., Hatzivassiliou, G., Sachdeva, U. M., Bui, T. V., Cross, J. R., & Thompson, C. B. (2009) · Science · doi:10.1126/science.1164097 · Cited by 2,298
HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption
Papandreou, I., Cairns, R. A., Fontana, L., Lim, A. L., & Denko, N. C. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.01.012 · Cited by 2,267
Gao, P., Tchernyshyov, I., Chang, T.-C., Lee, Y.-S., Kita, K., Ochi, T., Zeller, K. I., De Marzo, A. M., Van Eyk, J. E., Mendell, J. T., et al. (2009) · Nature · doi:10.1038/nature07823 · Cited by 2,124
Ward, P. S., Patel, J., Wise, D. R., Abdel-Wahab, O., Bennett, B. D., Coller, H. A., Cross, J. R., Fantin, V. R., Hedvat, C. V., Perl, A. E., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.01.020 · Cited by 2,020
Flagged first, then by citations
1 of the 43 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 201–300 of 1,003
Metabolic regulation of chromatin modifications and gene expression
Schvartzman, J. M., Thompson, C. B., & Finley, L. W. S. (2018) · Journal of Cell Biology · doi:10.1083/jcb.201803061 · Cited by 233
Coordinative metabolism of glutamine carbon and nitrogen in proliferating cancer cells under hypoxia
Wang, Y., Bai, C., Ruan, Y., Liu, M., Chu, Q., Qiu, L., Yang, C., & Li, B. (2019) · Nature Communications · doi:10.1038/s41467-018-08033-9 · Cited by 232
Arginine Methylation of MDH1 by CARM1 Inhibits Glutamine Metabolism and Suppresses Pancreatic Cancer
Wang, Y.-P., Zhou, W., Wang, J., Huang, X., Zuo, Y., Wang, T.-S., Gao, X. J., Xu, Y., Zou, S., Liu, Y., et al. (2016) · Molecular Cell · doi:10.1016/j.molcel.2016.09.028 · Cited by 230
Cancer Metabolism: Current Understanding and Therapies
Counihan, J. L., Grossman, E. A., & Nomura, D. K. (2018) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00775 · Cited by 236
MCT1 Modulates Cancer Cell Pyruvate Export and Growth of Tumors that Co-express MCT1 and MCT4
Hong, C. S., Graham, N. A., Gu, W., Camacho, C. E., Mah, V. H., Maresh, E. L., Alavi, M., Bagryanova, L., Krotee, P., Gardner, B. K., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.01.057 · Cited by 223
Kamphorst, J. J., Chung, M. K., Fan, J., & Rabinowitz, J. D. (2014) · Cancer & Metabolism · doi:10.1186/2049-3002-2-23 · Cited by 227
Lussey-Lepoutre, C., Hollinshead, K. E. R., Ludwig, C., Menara, M., Morin, A., Castro-Vega, L.-J., Parker, S. J., Janin, M., Martinelli, C., Ottolenghi, C., et al. (2015) · Nature Communications · doi:10.1038/ncomms9784 · Cited by 227
Self-citationModeling tumor cell adaptations to hypoxia in multicellular tumor spheroids
Riffle, S., & Hegde, R. S. (2017) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-017-0570-9 · Cited by 231
mTORC1 as a Regulator of Mitochondrial Functions and a Therapeutic Target in Cancer
de la Cruz-López, K. G., Toledo-Guzmán, M. E., Sánchez, E. O., & Carrancá, A. G. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01373 · Cited by 223
Turkalp, Z. T., Karamchandani, J., & Das, S. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2014.1205 · Cited by 222
Ni, Y., Qian, L., Siliceo, S. L., Long, X., Nychas, E., Liu, Y., Ismaiah, M. J., Leung, H., Zhang, L., Gao, Q., et al. (2023) · Cell Metabolism · doi:10.1016/j.cmet.2023.08.002 · Cited by 237
Burns, J. S., & Manda, G. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18122755 · Cited by 230
Oncogenic pathways and the electron transport chain: a dangeROS liaison
Raimondi, V., Ciccarese, F., & Ciminale, V. (2019) · British Journal of Cancer · doi:10.1038/s41416-019-0651-y · Cited by 232
Fumarate is a terminal electron acceptor in the mammalian electron transport chain
Spinelli, J. B., Rosen, P. C., Sprenger, H.-G., Puszynska, A. M., Mann, J. L., Roessler, J. M., Cangelosi, A. L., Henne, A., Condon, K. J., Zhang, T., et al. (2021) · Science · doi:10.1126/science.abi7495 · Cited by 221
ACSL4 reprograms fatty acid metabolism in hepatocellular carcinoma via c-Myc/SREBP1 pathway
Chen, J., Ding, C., Chen, Y., Hu, W., Yu, C., Peng, C., Feng, X., Cheng, Q., Wu, W., Lu, Y., et al. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.12.019 · Cited by 222
Abramczyk, H., Surmacki, J. M., Kopeć, M., Olejnik, A. K., Lubecka, K., & Fabianowska‐Majewska, K. (2015) · The Analyst · doi:10.1039/c4an01875c · Cited by 219
A Clearer View of the Molecular Complexity of Clear Cell Renal Cell Carcinoma
Frew, I. J., & Moch, H. (2014) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathol-012414-040306 · Cited by 230
The Metabolic Phenotype of Prostate Cancer
Eidelman, E. R., Twum-Ampofo, J. K., Ansari, J., & Siddiqui, M. M. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00131 · Cited by 219
The Warburg metabolism fuels tumor metastasis
Lu, J. (2019) · Cancer and Metastasis Reviews · doi:10.1007/s10555-019-09794-5 · Cited by 221
Acidosis induces reprogramming of cellular metabolism to mitigate oxidative stress
LaMonte, G., Tang, X., Chen, J. L.-Y., Wu, J., Ding, C. C., Keenan, M. M., Sangokoya, C., Kung, H., Ilkayeva, O., Boros, L. G., et al. (2013) · Cancer & Metabolism · doi:10.1186/2049-3002-1-23 · Cited by 228
Tumor hypoxia: From basic knowledge to therapeutic implications
Liao, C., Liu, X., Zhang, C., & Zhang, Q. (2023) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.12.011 · Cited by 223
Young, R. M., Ackerman, D., Quinn, Z. L., Mancuso, A., Gruber, M., Liu, L., Giannoukos, D. N., Bobrovnikova-Marjon, E. V., Diehl, J. A., Keith, B., et al. (2013) · Genes & Development · doi:10.1101/gad.198630.112 · Cited by 221
Immunometabolic circuits in trained immunity
Arts, R. J. W., Joosten, L. A. B., & Netea, M. G. (2016) · Seminars in Immunology · doi:10.1016/j.smim.2016.09.002 · Cited by 228
Chen, Q., Kirk, K., Shurubor, Y. I., Zhao, D., Arreguin, A. J., Shahi, I., Valsecchi, F., Primiano, G., Calder, E. L., Carelli, V., et al. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.03.002 · Cited by 210
Control of glutamine metabolism by the tumor suppressor Rb
Reynolds, M. R., Lane, A. N., Robertson, B., Kemp, S., Liu, Y., Hill, B. G., Dean, D. C., & Clem, B. F. (2014) · Oncogene · doi:10.1038/onc.2012.635 · Cited by 216
Metformin Antagonizes Cancer Cell Proliferation by Suppressing Mitochondrial-Dependent Biosynthesis
Griss, T., Vincent, E. E., Egnatchik, R. A., Chen, J., Ma, E. H., Faubert, B., Viollet, B., DeBerardinis, R. J., & Jones, R. G. (2015) · PLoS Biology · doi:10.1371/journal.pbio.1002309 · Cited by 216
Metabolic Diversity in Human Non-Small Cell Lung Cancer Cells
Chen, P.-H., Cai, L., Huffman, K. E., Yang, C., Kim, J., Faubert, B., Boroughs, L. K., Ko, B., Sudderth, J., McMillan, E. A., et al. (2019) · Molecular Cell · doi:10.1016/j.molcel.2019.08.028 · Cited by 209
Exploring the molecular interface between hypoxia-inducible factor signalling and mitochondria
Thomas, L. W., & Ashcroft, M. A. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03039-y · Cited by 219
Targeting OXPHOS and the electron transport chain in cancer; Molecular and therapeutic implications
Greene, J. P., Segaran, A., & Lord, S. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.02.002 · Cited by 215
Koizume, S., & Miyagi, Y. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17091430 · Cited by 213
Yao, C.-H., Liu, G., Wang, R., Moon, S. H., Gross, R. W., & Patti, G. J. (2018) · PLoS Biology · doi:10.1371/journal.pbio.2003782 · Cited by 222
Cytosolic Aspartate Availability Determines Cell Survival When Glutamine Is Limiting
Alkan, H. F., Walter, K. E., Luengo, A., Madreiter‐Sokolowski, C. T., Stryeck, S., Lau, A. N., Zoughbi, W. A., Lewis, C. A., Thomas, C. J., Höefler, G., et al. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.07.021 · Cited by 205
Deregulated Myc Requires MondoA/Mlx for Metabolic Reprogramming and Tumorigenesis
Carroll, P. A., Diolaiti, D., McFerrin, L. G., Gu, H., Djukovic, D., Du, J., Cheng, P. F., Anderson, S., Ulrich, M. L., Hurley, J. B., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2014.11.024 · Cited by 202
Oxygen availability and metabolic reprogramming in cancer
Xie, H. J., & Simon, M. C. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.r117.799973 · Cited by 207
Metabolic reprogramming in renal cancer: Events of a metabolic disease
Chakraborty, S., Balan, M., Sabarwal, A., Choueiri, T. K., & Pal, S. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188559 · Cited by 214
Dang, L., & Su, S.-S. M. (2017) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-061516-044732 · Cited by 204
Calvert, A. E., Chalastanis, A., Wu, Y., Hurley, L., Kouri, F. M., Bi, Y., Kachman, M. T., May, J., Bartom, E. T., Hua, Y., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.05.014 · Cited by 212
KRAS4A directly regulates hexokinase 1
Amendola, C. R., Mahaffey, J. P., Parker, S. J., Ahearn, I. M., Chen, W.-C., Zhou, M., Court, H., Shi, J., Mendoza, S. L., Morten, M. J., et al. (2019) · Nature · doi:10.1038/s41586-019-1832-9 · Cited by 203
Lipid metabolism emerges as a promising target for malignant glioma therapy
Guo, D., Bell, E. H., & Chakravarti, A. (2013) · CNS Oncology · doi:10.2217/cns.13.20 · Cited by 203
Self-citationŚwierczyński, J. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i9.2279 · Cited by 203
Chen, J., Guccini, I., Mitri, D. D., Brina, D., Revandkar, A., Sarti, M., Pasquini, E., Alajati, A., Pinton, S., Losa, M., et al. (2018) · Nature Genetics · doi:10.1038/s41588-017-0026-3 · Cited by 202
Gouw, A. M., Margulis, K., Liu, N. S., Raman, S. J., Mancuso, A., Toal, G. G., Tong, L., Mosley, A. R., Hsieh, A. L., Sullivan, D. K., et al. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.07.012 · Cited by 195
Oncogenic KRAS induces NIX-mediated mitophagy to promote pancreatic cancer
Humpton, T. J., Alagesan, B., DeNicola, G. M., Lu, D., Yordanov, G. N., Leonhardt, C. S., Yao, M. A., Alagesan, P., Zaatari, M. N., Park, Y., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1409 · Cited by 198
Fendt, S., Bell, E. L., Keibler, M. A., Davidson, S. M., Wirth, G. J., Fiske, B. P., Mayers, J. R., Schwab, M. G., Bellinger, G., Csibi, A., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-0080 · Cited by 196
Self-citationAn Essential Requirement for the SCAP/SREBP Signaling Axis to Protect Cancer Cells from Lipotoxicity
Williams, K. J., Argus, J. P., Zhu, Y., Wilks, M. Q., Marbois, B. N., York, A. G., Kidani, Y., Pourzia, A. L., Akhavan, D., Lisiero, D. N., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-0382-t · Cited by 197
CRY2 and FBXL3 Cooperatively Degrade c-MYC
Huber, A., Papp, S. J., Chan, A. B., Henriksson, E., Jordan, S. D., Kriebs, A., Nguyen, M., Wallace, M., Li, Z., Metallo, C. M., et al. (2016) · Molecular Cell · doi:10.1016/j.molcel.2016.10.012 · Cited by 203
Self-citationVasseur, S., & Guillaumond, F. (2022) · Oncogenesis · doi:10.1038/s41389-022-00420-8 · Cited by 203
Fischer, G. M., Gopal, Y. N. V., McQuade, J. L., Peng, W., DeBerardinis, R. J., & Davies, M. A. (2017) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12661 · Cited by 200
The cross talk between microbiota and the immune system: metabolites take center stage
Shapiro, H., Thaiss, C. A., Levy, M., & Elinav, E. (2014) · Current Opinion in Immunology · doi:10.1016/j.coi.2014.07.003 · Cited by 189
Small molecule activation of PKM2 in cancer cells induces serine auxotrophy
Kung, C., Hixon, J., Choe, S., Marks, K., Gross, S., Murphy, E., DeLaBarre, B., Cianchetta, G., Sethumadhavan, S., Wang, X., et al. (2012) · Chemistry & Biology · doi:10.1016/j.chembiol.2012.07.021 · Cited by 192
Metabolic adaptation of cancer and immune cells mediated by hypoxia-inducible factors
Samanta, D., & Semenza, G. L. (2018) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2018.07.002 · Cited by 190
The emerging role of fumarate as an oncometabolite
Yang, M., Soga, T., Pollard, P. J., & Adam, J. (2012) · Frontiers in Oncology · doi:10.3389/fonc.2012.00085 · Cited by 189
Direct Visualization of De novo Lipogenesis in Single Living Cells
Li, J., & Cheng, J. (2014) · Scientific Reports · doi:10.1038/srep06807 · Cited by 183
Filipp, F. V., Scott, D. A., Ronai, Z. A., Osterman, A. L., & Smith, J. W. (2012) · Pigment Cell & Melanoma Research · doi:10.1111/j.1755-148x.2012.00989.x · Cited by 193
Famine versus feast: understanding the metabolism of tumors in vivo
Mayers, J. R., & Heiden, M. G. V. (2015) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2015.01.004 · Cited by 190
Moreno‐Sánchez, R., Marín‐Hernández, Á., Saavedra, E., Pardo, J. P., Ralph, S. J., & Rodríguez‐Enríquez, S. (2014) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2014.01.025 · Cited by 189
Modeling cancer metabolism on a genome scale
Yizhak, K., Chaneton, B., Gottlieb, E., & Ruppin, E. (2015) · Molecular Systems Biology · doi:10.15252/msb.20145307 · Cited by 187
The mitochondrial citrate transporter, CIC, is essential for mitochondrial homeostasis
Catalina-Rodriguez, O., Kolukula, V. K., Tomita, Y. A., Preet, A., Palmieri, F., Wellstein, A., Byers, S. W., Giaccia, A. J., Glasgow, E. F., Albanese, C., et al. (2012) · Oncotarget · doi:10.18632/oncotarget.714 · Cited by 190
Stegen, S., van Gastel, N., Eelen, G., Ghesquière, B., D’Anna, F., Thienpont, B., Goveia, J., Torrekens, S., Looveren, R. V., Luyten, F. P., et al. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.01.002 · Cited by 194
Disorders of cancer metabolism: The therapeutic potential of cannabinoids
Sun, D., Li, X., Nie, S., Liu, J., & Wang, S. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113993 · Cited by 195
Glutamine Transport and Mitochondrial Metabolism in Cancer Cell Growth
Scalise, M., Pochini, L., Galluccio, M., Console, L., & Indiveri, C. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00306 · Cited by 183
Resistance to BRAF inhibitors induces glutamine dependency in melanoma cells
Baenke, F., Chaneton, B., Smith, M., van den Broek, N. J. F., Hogan, K., Tang, H., Virós, A., Martin, M. J., Galbraith, L. C. A., Girotti, M. R., et al. (2015) · Molecular Oncology · doi:10.1016/j.molonc.2015.08.003 · Cited by 191
The GSK3 Signaling Axis Regulates Adaptive Glutamine Metabolism in Lung Squamous Cell Carcinoma
Momcilovic, M., Bailey, S. T., Lee, J. T., Fishbein, M. C., Braas, D., Go, J. L., Graeber, T. G., Parlati, F., Demo, S. D., Li, R., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.04.002 · Cited by 187
Metabolic Plasticity in Chemotherapy Resistance
Desbats, M. A., Giacomini, I., Prayer‐Galetti, T., & Montopoli, M. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00281 · Cited by 190
Targeting Glutamine Induces Apoptosis: A Cancer Therapy Approach
Chen, L., & Cui, H. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms160922830 · Cited by 184
Molenaar, R. J., Radivoyevitch, T., Maciejewski, J. P., Noorden, C. J. F. V., & Bleeker, F. E. (2014) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2014.05.004 · Cited by 186
Wang, Z., Liu, F., Fan, N., Zhou, C., Li, D., MacVicar, T., Dong, Q., Bruns, C. J., & Zhao, Y. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.589508 · Cited by 189
Ward, P. S., Lü, C., Cross, J. R., Abdel-Wahab, O. I., Levine, R. L., Schwartz, G. K., & Thompson, C. B. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.435495 · Cited by 188
Maftouh, M., Avan, A., Sciarrillo, R., Granchi, C., Leon, L., Rani, R., Funel, N., Smid, K., Honeywell, R. J., Boggi, U., et al. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.681 · Cited by 183
Inhibition of Mitochondrial Complex II by the Anticancer Agent Lonidamine
Guo, L., Shestov, A. A., Worth, A. J., Nath, K., NELSON, D. S., Leeper, D. B., Glickson, J. D., & Blair, I. A. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.697516 · Cited by 187
Fatty acid metabolism reprogramming in ccRCC: mechanisms and potential targets
Tan, S. K., Hougen, H. Y., Merchan, J. R., Gonzalgo, M. L., & Welford, S. M. (2022) · Nature Reviews Urology · doi:10.1038/s41585-022-00654-6 · Cited by 181
Metabolic heterogeneity in cancer
Demicco, M., Liu, X., Leithner, K., & Fendt, S. (2024) · Nature Metabolism · doi:10.1038/s42255-023-00963-z · Cited by 186
Exploiting the bad eating habits of Ras-driven cancersPreprint
White, E. (2013) · Genes & Development · doi:10.1101/gad.228122.113 · Cited by 183
Metabolic reprogramming and metabolic dependency in T cells
Wang, R., & Green, D. R. (2012) · Immunological Reviews · doi:10.1111/j.1600-065x.2012.01155.x · Cited by 180
Cassim, S., Vučetić, M., Ždralević, M., & Pouysségur, J. (2020) · Cancers · doi:10.3390/cancers12051119 · Cited by 183
Hypoxia, endoplasmic reticulum stress and chemoresistance: dangerous liaisons
Akman, M., Belisario, D. C., Salaroglio, I. C., Kopecka, J., Donadelli, M., Smaele, E. D., & Riganti, C. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01824-3 · Cited by 179
OGDHL silencing promotes hepatocellular carcinoma by reprogramming glutamine metabolism
Dai, W., Xu, L., Yu, X., Zhang, G., Guo, H., Liu, H., Song, G., Weng, S., Dong, L., Zhu, J., et al. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.12.015 · Cited by 174
Cancer cell metabolism and mitochondria: Nutrient plasticity for TCA cycle fueling
Corbet, C., & Féron, O. (2017) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2017.01.002 · Cited by 174
Metabolic rewiring in melanoma
Ratnikov, B. I., Scott, D. A., Osterman, A. L., Smith, J. W., & Ronai, Z. A. (2016) · Oncogene · doi:10.1038/onc.2016.198 · Cited by 176
Targeted inhibition of EGFR and glutaminase induces metabolic crisis in EGFR mutant lung cancer
Momcilovic, M., Bailey, S. T., Lee, J. T., Fishbein, M. C., Magyar, C., Braas, D., Graeber, T., Jackson, N. J., Czernin, J., Emberley, E., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2016.12.061 · Cited by 157
Amino Acid Transporters and Glutamine Metabolism in Breast Cancer
Cha, Y. J., Kim, E.-S., & Koo, J. S. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19030907 · Cited by 167
Wang, Y.-Q., Wang, H.-L., Xu, J., Tan, J., Fu, L., Wang, J., Zou, T., Sun, D., Gao, Q., Chen, Y., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-02951-4 · Cited by 169
Corbet, C., Draoui, N., Polet, F., Pinto, A., Drozak, X., Riant, O., & Feron, O. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0705 · Cited by 169
The expanded role of fatty acid metabolism in cancer: new aspects and targets
Chen, M., & Huang, J. (2019) · Precision Clinical Medicine · doi:10.1093/pcmedi/pbz017 · Cited by 172
Targeting SLC1a5 ‐mediated glutamine dependence in non‐small cell lung cancer
Hassanein, M., Qian, J., Hoeksema, M. D., Wang, J., Jacobovitz, M. R., Ji, X., Harris, F. T., Harris, B. K., Boyd, K. L., Chen, H., et al. (2015) · International Journal of Cancer · doi:10.1002/ijc.29535 · Cited by 168
HIF-1-Independent Mechanisms Regulating Metabolic Adaptation in Hypoxic Cancer Cells
Lee, S.-H., Golinska, M., & Griffiths, J. R. (2021) · Cells · doi:10.3390/cells10092371 · Cited by 169
VHL Deficiency Drives Enhancer Activation of Oncogenes in Clear Cell Renal Cell Carcinoma
Yao, X., Tan, J. Y., Lim, K. J., Koh, J., Ooi, W. F., Li, Z., Huang, D., Xing, M., Chan, Y. S., Qu, J. Z., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0375 · Cited by 171
What do we know about IDH1/2 mutations so far, and how do we use it?
Horbinski, C. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1106-9 · Cited by 169
Inhibition of Mitochondrial Aconitase by Succination in Fumarate Hydratase Deficiency
Ternette, N., Yang, M., Laroyia, M., Kitagawa, M., O’Flaherty, L., Wolhulter, K., Igarashi, K., Saito, K., Kato, K., Fischer, R., et al. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.02.013 · Cited by 158
Simoes, R. V., Serganova, I. S., Kruchevsky, N., Leftin, A., Shestov, A. A., Thaler, H. T., Sukenick, G. D., Locasale, J. W., Blasberg, R. G., Koutcher, J. A., et al. (2015) · Neoplasia · doi:10.1016/j.neo.2015.08.005 · Cited by 161
Varone, A., Xylas, J. F., Quinn, K. P., Pouli, D., Sridharan, G. V., McLaughlin-Drubin, M. E., Alonzo, C., Lee, K., Münger, K., & Georgakoudi, I. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2713 · Cited by 163
Leonardi, R., Subramanian, C., Jackowski, S., & Rock, C. O. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.c112.353946 · Cited by 171
Fumarate hydratase in cancer: A multifaceted tumour suppressor
Schmidt, C., Sciacovelli, M., & Frezza, C. (2019) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2019.05.002 · Cited by 166
TCA Cycle Defects and Cancer: When Metabolism Tunes Redox State
Cardaci, S., & Ciriolo, M. R. (2012) · International Journal of Cell Biology · doi:10.1155/2012/161837 · Cited by 169
Oncogenic regulation of tumor metabolic reprogramming
Tarrado‐Castellarnau, M., de Atauri, P., & Cascante, M. (2016) · Oncotarget · doi:10.18632/oncotarget.10911 · Cited by 165
Genetic and metabolic hallmarks of clear cell renal cell carcinoma
Sanchez, D. J., & Simon, M. C. (2018) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2018.06.003 · Cited by 164
Therapeutic targeting of glutaminolysis as an essential strategy to combat cancer
Matés, J. M., Paola, F. J. D., Campos-Sandoval, J. A., Mazurek, S., & Márquez, J. (2019) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2019.05.012 · Cited by 169
Caravella, J. A., Lin, J., Diebold, R. B., Campbell, A.-M., Ericsson, A. M., Gustafson, G. R., Wang, Z., Castro, J., Clarke, A., Gotur, D., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01423 · Cited by 162
Glucose-dependent de Novo Lipogenesis in B Lymphocytes
Dufort, F. J., Gumina, M. R., Ta, N. L., Tao, Y., Heyse, S. A., Scott, D. A., Richardson, A. D., Seyfried, T. N., & Chiles, T. C. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.551051 · Cited by 160
Ahn, W. S., & Antoniewicz, M. R. (2013) · Metabolic Engineering · doi:10.1016/j.ymben.2012.10.001 · Cited by 160
Metadata
- Authors
- Metallo, C. M., Gameiro, P. A., Bell, E. L., Mattaini, K. R., Yang, J., Hiller, K., Jewell, C. M., Johnson, Z. R., Irvine, D. J., Guarente, L., Kelleher, J. K., Vander Heiden, M. G., Iliopoulos, O., & Stephanopoulos, G.
- Affiliations
- Massachusetts Institute of Technology (US)
- Massachusetts General Hospital (US)
- Howard Hughes Medical Institute (US)
- Corresponding author
- Iliopoulos, Othon
- Stephanopoulos, Gregory
- ORCID
- Venue
- Nature
- Published
- 2011-11-20
- Volume
- 481
- Issue
- 7381
- Pages
- 380-384
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC3710581
- OpenAlex
- W2116516144
- Cited by
- 1,791
- References
- 43
- Citations by year
- 2026: 82 · 2025: 95 · 2024: 96 · 2023: 137 · 2022: 156 · 2021: 143 · 2020: 149 · 2019: 125 · 2018: 100 · 2017: 135 · 2016: 129 · 2015: 125 · 2014: 119 · 2013: 112 · 2012: 84
- FWCI
- 34.61
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- DSpace@MIT (Massachusetts Institute of Technology) (submittedVersion, cc-by-nc-sa)
- RePEc: Research Papers in Economics (submittedVersion)
- Open Repository and Bibliography (University of Luxembourg) (submittedVersion)
- Funders
- Howard Hughes Medical Institute
- Damon Runyon Cancer Research Foundation
- Wellcome Trust
- Agios Pharmaceuticals
- National Institutes of Health
- National Cancer Institute (R01CA160458, R01CA122591, P30CA014051)
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK075850)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Amino Acid Enzymes and Metabolism
- Keywords
- IDH1, lipogenesis, hypoxia, reductive carboxylation, alpha-ketoglutarate, acetyl-CoA, fatty acid synthesis, VHL, renal cell carcinoma, cancer metabolism, mitochondrial dysfunction, aerobic glycolysis
- MeSH terms
- Endothelial PAS Domain-Containing Protein 1, Acetyl Coenzyme A, Carbon, Carcinoma, Renal Cell, Cells, Cultured, Citric Acid Cycle, Glutamine, Humans, Isocitrate Dehydrogenase, Ketoglutaric Acids, Kidney Neoplasms, Oxidation-Reduction, Oxygen, Cell Hypoxia, CD8-Positive T-Lymphocytes, Palmitic Acid, Cell Line, Tumor, Lipogenesis, Aryl Hydrocarbon Receptor Nuclear Translocator, Basic Helix-Loop-Helix Transcription Factors, Basic Helix-Loop-Helix Proteins, Von Hippel-Lindau Tumor Suppressor Protein, Hypoxia-Inducible Factor 1, alpha Subunit
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
